This biomarker is also known as:
- Endothelin Receptor Type B,
- Endothelin B Receptor,
- Endothelin Receptor Non-Selective Type,
View in BioMuta
From Entrez Gene:
The protein encoded by this gene is a G protein-coupled receptor which activates a phosphatidylinositol-calcium second messenger system. Its ligand, endothelin, consists of a family of three potent vasoactive peptides: ET1, ET2, and ET3. Studies suggest that the multigenic disorder, Hirschsprung disease type 2, is due to mutations in the endothelin receptor type B gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. (provided by RefSeq, Jan 2011)
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Head & neck, NOS
No additional data available.
EDNRB is one of eight genes on a panel of differentially methylated genes from normal and OSCC clinical samples from patients with heterogenous risk profiles chosen for further validation. The eight genes are: HOXA9, NID2, GATA4, KIF1A, EDNRB, MCAM, DCC, and CALCA.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.